Gilead Sciences (GILD) recently drew attention after the FDA accepted its New Drug Application for a once daily bictegravir and lenacapavir HIV tablet. The application was granted priority review, supported by Phase 3 data and positive tolerability findings.

The stock has reacted to the FDA priority review and upcoming earnings with a 2.11% 1 day share price return and 5.79% 7 day share price return. However, the 30 and 90 day share price returns are still negative, so recent momentum is building on top of longer term weakness even as the 1 year and multi year total shareholder returns remain strong.

If the HIV update has your attention, it can be useful to see what else is moving across healthcare related AI opportunities, starting with the 32 healthcare AI stocks

With Gilead trading at US$136.30 and sitting at a reported 53% intrinsic discount and about 16% below analyst targets, you have to ask: is this a genuine value setup, or is the market already baking in future growth?

Most Popular Narrative: 13.4% Undervalued

Against the last close of $136.30, the most followed narrative is working off a fair value of $157.43. It builds a detailed case around future HIV and oncology cash flows under a 7.31% discount rate.

The launch and scaling of innovative products (Yeztugo, Trodelvy first line, Livdelzi) position Gilead to deliver a more favorable product mix and premium pricing, driving higher gross margins and improving long term earnings trajectory as portfolio diversification reduces overexposure to legacy products.

Curious what earnings path and margin profile are being pencilled in to reach that fair value, and what future multiple the narrative leans on to get there? The full narrative spells out the revenue build, profitability assumptions and valuation bridge that connect today’s price to that $157.43 figure.

Result: Fair Value of $157.43 (UNDERVALUED)

However, this hinges on HIV remaining resilient and oncology delivering, while policy or pricing shifts and post-2033 patent cliffs could quickly challenge those fair value assumptions.

Next Steps

If this mix of optimism and concern has you torn, do not wait for a consensus to form. Instead, check the data yourself with the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Gilead has you thinking more broadly about your portfolio, do not stop here. Use focused stock lists to spot opportunities that might otherwise slip past you.

• Target quality at a discount by scanning companies that pass tight fundamentals filters with the 44 high quality undervalued stocks
• Prioritize resilience by checking out companies that stand out in the 74 resilient stocks with low risk scores
• Get early to potential future leaders by reviewing the screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.